MEDS WEST

July 31 - August 3, 2019
San Diego, CA

MEDS EAST

October 2 - 5, 2019
Caribe Royale, Orlando, FL

Session Description & Objectives

We are in the process of putting together the Metabolic & Endocrine Disease Summit (MEDS) program. 
Please SIGN UP for email updates to keep informed of program developments for our upcoming conference as they become available.

 

SIGN UP FOR UPDATES

 

Course Objectives
 

Right Between the Eyes: Suspecting Pituitary Disorders
Ji Hyun (CJ) Chun, PA-C, MPAS, BC-ADM
1. Describe medically relevant anatomy and physiology of the pituitary gland.
2. Outline appropriate evaluation of pituitary adenomas and function.
3. Describe common functional pituitary adenomas (prolactinoma, acromegaly).

Considering Cushing’s Disease: Yours to Keep or Refer?
Scott Urquhart, PA–C, DFAAPA
1. Review the obvious and subtle clinical presentations of hypercortisolemia and other clinical conditions that resemble it.
2. Describe the work-up and treatment of hypercortisolemia as it relates to Cushing’s Syndrome /disease and appropriate endocrine referral.

Adrenal Insufficiency / Adrenal Fatigue: Fact vs. Fiction
Scott Urquhart, PA–C, DFAAPA
1. Analyze etiologies, clinical presentation, work-up, and management of primary adrenal insufficiency.
2. Clarify the facts and dispel the myths surrounding “Adrenal Fatigue”.
3. Provide clinical direction and pearls to properly screen for “Adrenal Fatigue”.

Pheochromocytoma / Adrenal Incidentaloma: Yours to Keep or Refer?
Scott Urquhart, PA–C, DFAAPA
1. Examine the presentation of pheochromocytoma and implement a simple work-up for diagnosis and proper referral.
2. Discuss incidentally discovered adrenal adenomas with respect to initial discovery, imaging, work-up, treatment, follow-up, and when to refer.

New Therapies for the Treatment of Hypercholesterolemia: How to Use Them
Joyce L. Ross, MSN, ANP, CLS, CRNP, FPCNA, FNLA
1. Recall classes of dyslipidemic medications and the appropriate use for each.
2. Identify how treatment decisions apply to the most recent clinical guidelines.
3. Apply current knowledge to cases.

Weighing in on Obesity through the Lifespan: Causes, Complications, and Clinical Considerations
Christine Kessler, MN, ANP-BC, CNS, BC-ADM, FAANP
1. Review the latest epidemiologic factors likely influencing the rise of obesity in this country.
2. Describe various interconnections between fat (& selected adipokines), gut incretins & and neuropeptides in relation to satiety, calorie utilization, addictions and mood.
3. Correlate selected obesity co-morbidities to abnormal adipokine release and enteroendocrine function.
4. Relate the physiologic impact of various behavioral, pharmacologic and surgical intervention strategies in obesity prevention and treatment.
5. Review the efficacy of common over-the-counter weight loss remedies.

Preventing Toxic Metabolic Encephalopathy in Your At-Risk Patients
Joyce L. Ross, MSN, ANP, CLS, CRNP, FPCNA, FNLA
1.  Name five (5) risk factors that contribute to vascular disease.
2.  List the components of the metabolic syndrome that contribute to the risk of developing vascular disease.
3.  Apply knowledge to case studies to reduce vascular risks using non-pharmaceutical and pharmaceutical interventions.

Case Studies in Type 2 Diabetes: Achieving Goals Together - A Gluco-Patient Centric Approach
Presenters: Scott Urquhart, PA-C, DFAAPA
Lucia M. Novak, MSN, ANP-BC, BC–ADM, CDTC
1. Review the current ADA/EASD, and AACE guidelines for pharmacologic management of diabetes.
2. Critique the pharmacologic options with their expected A1c reductions, side-effect profiles and safety concerns.
3. Apply a glucose-centric approach to incorporate oral and non-insulin injectable agents in the treatment of patients with type 2 diabetes.
4. Demonstrate how a patient-centric approach promotes empowerment and positive outcomes.

Diabetes Medications: Making CO$$TLY Decisions
Presenters: Scott Urquhart, PA-C, DFAAPA
Lucia M. Novak, MSN, ANP-BC, BC–ADM, CDTC
1. Identify some of the challenges faced when evaluating and treating patients.
2. Discuss initial therapy options and review obstacles to advancing therapy.
3. Identify possible community resources that may help with adherence and compliance.

Insulin Overview: Which Type and Why
Davida F. Kruger, MSN, APRN–BC, BC–ADM
1. Identify a variety of insulin options available to treat people with diabetes.
2. Verbalize the difference in potency between u-100 insulin, and u-500 insulin.
3. Identify insulin available in vials and insulin pens.
4. Verbalize insulin on the horizon. 
5. Effectively write a prescription for insulin.

Case Studies continued: Moving Beyond Your Comfort Zone
Presenters: Donna Jornsay, MS, BSN, CPNP, CDE, BC-ADM, CDTC
Davida F. Kruger, MSN, APRN–BC, BC–ADM
1. Through the use of a case presentation the attendee will be able to verbalize when and how to initiate insulin as well as tactics to support the patient to be successful.
2. Attendees will be able to verbalize the variety of insulins available as well as devices available to administer.
3. Attendees will be able to recognize potential barriers to starting insulin and the support and education the patient requires to be successful. 

Nephrology Secrets: Diabetic Kidney Disease (DKD) and Hypertension
Kim Zuber, PA-C, MS
1. Identify the stages of kidney disease highlighting risk factors that predict progression of CKD.
2. Highlight goals of diabetic management from multiple sources including kidney and diabetic experts.
3. Discuss urine testing with emphasis on acceptable lab deviations that may affect patient care.
4. Using CKD stages, identify diabetic medications that are safe to use in each stage including FDA alerts.
5. Using a sample patient, discuss who/when/how to treat the CKD diabetic patient.

Numb Toes and Other Woes: Diabetic Peripheral and Autonomic Neuropathies
Lucia M. Novak, MSN, ANP–BC, BC–ADM, CDTC
1. Describe the microvascular complications of diabetic peripheral and autonomic neuropathy that affect patients suffering from diabetes mellitus.
2. Identify the clinical manifestations of these microvascular complications.
3. Apply current screening recommendations to ensure patients receive timely care.

Type 2 Diabetes, Pre-Diabetes and Reproductive Concerns
Donna Jornsay, MS, BSN, CPNP, CDE, BC-ADM, CDTC
1. Participants will describe the pathophysiology of type 2 diabetes in children.
2. Participants will identify one strategy for decreasing obesity in children.
3. Participants can state the number of hours of physical activity needed to prevent pre-diabetes from becoming type 2 diabetes in children.
4. Identify the complications related to presentational DM that can affect mom and baby during pregnancy.

Adult Onset Diabetes: Which Type is it?
Ji Hyun (CJ) Chun, PA-C, MPAS, BC-ADM
1. Describe the pathophysiology of the autoimmune destruction involved Type 1 diabetes.
2. Explain how to properly diagnose T1D.
3. Describe the features suggestive of Type 1 diabetes or latent autoimmune diabetes in adults (LADA).

Up, Up, and Away!  Grounding Glucocorticoid-Induced Hyperglycemia
Lucia M. Novak, MSN, ANP–BC, BC–ADM, CDTC
1. Recognize the pattern of glucocorticoid (GC)-induced hyperglycemia.
2. Identify the insulin profile best suited to address this pattern of hyperglycemia.
3. Determine how to dose insulin therapy using a weight-based approach.

Key Points to Know for Emerging Adults with Type 1 Diabetes
Donna Jornsay, MS, BSN, CPNP, CDE, BC-ADM, CDTC
1. Participants will be able to identify one behavior of emerging adults which threatens glycemic control.
2. Participants will state one practice change they can implement to assist this group in maintaining/establishing control.

Tips for Effective Communication in Diabetes Management
Moderator: Ellen D. Mandel, DMH, MPA, MS, PA–C, RD, CDE
Presenter: Donna Jornsay, MS, BSN, CPNP, CDE, BC-ADM, CDTC
1. Discuss the most recently published research that provides guidance to proper language and communication to persons with diabetes.
2. Demonstrate effective ways of communicating that will enhance a more meaningful patient / clinician relationship to improve diabetes outcomes.

Managing Thyroid Disease: Preparing for Battle
Moderator: Christine Kessler, MN, ANP-BC, CNS, BC-ADM, FAANP
Presenter: Chris Sadler, MA, PA–C, CDE, DFAAPA
1. Identify appropriate patients for thyroid screening and which laboratory/ancillary studies should be done.
2. Analyze thyroid laboratory data to accurately identify clinical & subclinical hypothyroidism & hyperthyroidism.
3. Identify drug or conditions that may interfere with the accuracy of these labs.
4. Demonstrate how to perform more effective thyroid palpation.

Case Studies in Hypo- and Hyperthyroidism for Clinical Consideration
Presenters: Christine Kessler, MN, ANP-BC, CNS, BC-ADM, FAANP
Chris Sadler, MA, PA–C, CDE, DFAAPA
1. Discuss pertinent physical assessment and laboratory studies to aid in diagnosis of clinical and subclinical hyper- & hypothyroidism.
2. Develop strategies to safely initiate, titrate, monitor and maintain ATD & THR (including desiccated thyroid hormone) therapy.
3. Address controversies surrounding management of subclinical hyper- & hypothyroidism.
4. Identify triggers and early symptoms of acute thyrotoxicosis (thyroid storm) and myxedema coma.

Thyroid Concerns in Pregnancy
Christine Kessler, MN, ANP-BC, CNS, BC-ADM, FAANP
1. Identify patients with subclinical hypothyroidism who requiring thyroid hormone replacement during pregnancy.
2.Describe how to change dosing of antithyroid drug (ADT) and thyroid hormone replacement during pregnancy.
3. Discuss risks to the unborn child incurred by uncontrolled hyper- or hypothyroidism.

Managing the "Hot" Mess of Thyroiditis
Moderator: Christine Kessler, MN, ANP-BC, CNS, BC-ADM, FAANP
Presenter: Christopher E. Sadler, MA, PA-C, CDE
1. State the signs, symptoms and presentation of different forms of thyroiditis.
2. Describe the diagnostic work-up for thyroiditis.
3. Interpret laboratory and thyroid scan data in the diagnosis of thyroiditis.

Expert Tips on Evaluating Thyroid Nodules
Chris Sadler, MA, PA–C, CDE, DFAAPA
1. Discuss how common thyroid nodules are in the general population and that most typify benign disease.
2. List ultrasound characteristics that increase suspicion of malignant disease.
3. Discuss appropriate ongoing follow-up of thyroid nodules.
4. Describe laboratory testing recommended for the work up of a newly found thyroid nodule(s).

Lifestyle Interventions: A New Narrative for Diabetes Management & Metabolic Health
Ellen D. Mandel, DMH, MPA, MS, PA–C, RD, CDE
1. List recommendation components of the 2017 American Diabetes Association “Lifestyle Management”.
2. Describe components of diet types challenging our patients’ decision-making.
3. Explain how sugar is not the only target.
4. Correlate activity and health: diet Is not the only approach.
5. Describe the relationship between diabetes self-management education and long-term success.

Gut Grief: The Enteroendocrine Connection in Autoimmune Diseases
Christine Kessler, MN, ANP-BC, CNS, BC-ADM, FAANP
1. Describe symptoms and presentation of patients with celiac disease, post-bariatric surgery, gastroparesis and enteropathy.
2. Review diagnostic and treatment considerations for each condition.
3. Discuss strategies for improving blood glucose control in patients affected by these GI conditions.

Mind and Body: The Vicious Cycle of Depression in Diabetes and Chronic Illness
Ellen D. Mandel, DMH, MPA, MS, PA–C, RD, CDE
1. List the incidence and predictors of depression and diabetes.
2. Correlate disordered eating with diabetes risk.
3. Explain the intersection of dementia, depression and diabetes.
4. Describe the effect of PTSD on diabetes.

Cold Case Studies in Renal Medication Dosing: The Good, the Bad and the Iatrogenic
Kim Zuber, PAC, MS
1. By CKD stage, review common medications taken by CKD patients.
2. By CKD stage, review common dosing errors and the pathological rationale for medication selection.
3. Using patient examples, discuss medication errors commonly found for CKD patients.
4. Give a quick overview of the OTC meds dangerous for the CKD patient.
5. Discuss the relationship between AKI and CKD for the non-nephrology practitioner.

PCOS Update 2018
R. Mimi Secor, DNP, FNP-BC, FAANP
1. Describe epidemiology, pathophysiology, risks, complications, signs, symptoms.
2. Explain recommendations for diagnosing PCOS, including controversies.
3. Discuss lifestyle and pharmacologic approaches to managing PCOS.

Hypercalcemia, Parathyroid Disease Unraveled: 3 Cases to Consider
Presenters: Ji Hyun (CJ) Chun, PA-C, MPAS, BC-ADM
Scott Urquhart, PA–C, DFAAPA
1. Discuss Hypercalcemia and common causes.
2. Discuss workup and treatment strategies.
3. Discuss role of Vitamin D and its impact on calcium/parathyroid disorders.
4. Discuss risk factors that should prompt screening for Vitamin D deficiency.
5. Discuss known as well as potential consequences of Vitamin D deficiency.

Osteoporosis: Sticks and Stones May or May Not Break My Bones?
Richard S. Pope, MPAS, PA–C, DFAAPA, CPAAPA
1. Apply NOF/WHO criteria to make the diagnosis of osteoporosis.
2. Decipher what tests are needed in individual patients given their history and risk factors for fracture.
3. Develop strategies to manage your patient’s skeletal health and decrease their risk of fracture. 
3. Compare and critique different mechanisms of action for FDA approved OP medications.
  4. Summarize the best choices for treatment given specific patient examples.

Osteoporosis: Case Studies for Consideration
Moderator: R. Mimi Secor, DNP, FNP-BC, FAANP
Presenter: Richard S. Pope, MPAS, PA–C, DFAAPA, CPAAPA
1. Discuss case studies as they pertain to assessing risk of osteoporosis and best work up.
2. Explain diagnostic workup based on assessment.
3. Describe treatment options based on case studies.

Men’s and Women’s Health Issues and Endocrine Disease
Ji Hyun (CJ) Chun, PA-C, MPAS, BC-ADM
1. Review current evidence in testosterone replacement therapy in elderly males.
2. Review a comprehensive diagnostic protocol to differentiate pathologic vs physiologic hypogonadism.
3. Outline appropriate monitoring of patients on testosterone replacement therapy.
R. Mimi Secor, DNP, FNP-BC, FAANP
1. Describe epidemiology of menopause, Vasomotor Symptoms (VMS) and Vulvovaginal Atrophy (VVA).
2. Discuss diagnosis of VMS and Vulvovaginal Atrophy.       
3. Explain options for treatment of VMS and VVA.

Multi-Specialty Bone Panel
Panelists: Ji Hyun (CJ) Chun, PA-C, MPAS, BC-ADM
Richard S. Pope, MPAS, PA–C, DFAAPA, CPAAPA
R. Mimi Secor, DNP, FNP-BC, FAANP
Scott Urquhart, PA–C, DFAAPA
Kim Zuber, PAC, MS
1. Discuss the differences in the risk for and etiology of bone fragility due to general osteoporosis, menopause, calcium-related endocrinopathies, and kidney disease.
2. Identify prevention of and treatment priorities for bone fragility due to osteoporosis, menopause, calcium-related endocrinopathies, and kidney disease.

Follow Us

Jointly Provided By

In Association With